SynAct Pharma’s COO sells shares to cover tax on holdings

SynAct Pharma AB (publ) (“SynAct”) today announced that its Chief Operating Officer (COO), Thomas Boesen, through his holding company, has sold 42,747 shares in SynAct. The sales correspond to 28 percent of his shareholdings and is in accordance with his lock-up agreement. After the divestment, Boesen owns 112,580 shares. The proceeds will be used to pay for Danish tax on holdings of his SynAct shares. Thomas Boesen remains an active member of management with long-term commitment and interests in the company.

Under Danish tax law, tax on holdings is due for shares in a publicly traded company, such as SynAct, when the shares are held through a limited liability company and the total shareholding is less than 10 percent of the publicly traded company. The tax on holdings is calculated based on value increase in the calendar year (in this case 2021). Regardless of the capital gain being materialized through selling of the shares or not.

The transactions are reported to the Swedish Financial Supervisory Authority (Sv. Finansinspektionen) as required under current regulation.

The information was submitted, through the agency of the contact person below, for publication at 08:45 a.m CEST on December 14, 2022.